Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemaket up 0.1% despite 'volatile' markets
Markets Market Close

NZ sharemaket up 0.1% despite 'volatile' markets

The S&P/NZX 50 Index closed at 12,338.57, up 18.38 points or 0.15%.

Graham Skellern 03 Apr 2025
NZX-listed companies take stock in wake of US tariff moves
Economy

NZX-listed companies take stock in wake of US tariff moves

Wine makers, manufacturers and others mull what trade wars will bring.

Ian Llewellyn 03 Apr 2025
Analysts struggle to find upside from Trump tariffs
Economy

Analysts struggle to find upside from Trump tariffs

‘They've forgotten the lessons of the Great Depression,’ one analyst said.

Gregor Thompson 03 Apr 2025
S&P/ASX200 takes a tumble on Trump's Liberation Day, Asia to follow suit
Markets

S&P/ASX200 takes a tumble on Trump's Liberation Day, Asia to follow suit

The fall may be short lived now there is more certainty. 

Rebecca Howard 03 Apr 2025